Fondaparinux was noninferior to enoxaparin for death, MI, and refractory ischemia but reduced bleeding in angina and non-STEMI

September 2006
ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p31
Academic Journal
The article presents information on a clinical trial related to the use of the drugs fondaparinux and enoxaparin in patients suffering from acute coronary syndromes. It was found that in patients with non-STsegment elevation myocardial infarction (MI) or unstable angina, fondaparinux was noninferior to enoxaparin for reducing death, MI, and refractory ischemia.


Related Articles

  • Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction. Betancourt, Blas Y; Marrero-Miragaya, María A; Jiménez-López, Giset; Valenzuela-Silva, Carmen; García-Iglesias, Elizeth; Hernández-Bernal, Francisco; Debesa-García, Francisco; González-López, Tania; Alvarez-Falcón, Leovaldo; López-Saura, Pedro A // BMC Clinical Pharmacology;2005, Vol. 5, p5 

    Background: Streptokinase (SK) is an effective fibrinolytic agent for the treatment of acute myocardial infarction (AMI). The objective of the present study was to assess the adverse drug reactions (ADRs) associated with intravenous recombinant SK in patients with AMI in routine clinical...

  • Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. McMurray, John J. V. // Heart;Jul2001, Vol. 86 Issue 1, p97 

    Two landmark clinical trials, CONSENSUS I and SOLVD-T, have shown, unequivocally, that angiotensin converting enzyme (ACE) inhibitors reduce all cause mortality in patients with chronic heart failure and underlying left ventricular systolic dysfunction. A number of other key randomized,...

  • No benefit, possible harm with GIK infusion for STEMI.  // Reactions Weekly;12/8/2007, Issue 1181, p1 

    This article reports on the conclusion by clinical trial investigators that glucose/insulin/potassium (GIK) therapy has no clinical benefit and may even cause early harm in patients with ST-segment elevation myocardial infarction. The number of patients involved in the clinical trial was 1,374...

  • CVT opens first FGF-1 site.  // Cardiovascular Devices & Drugs;Oct2008, Vol. 14 Issue 10, p11 

    The article reports on the opening of the first U.S. site for patient enrollment for CardioVascular BioTherapeutics' (CBVT) Phase II clinical trial for the treatment of severe coronary heart disease. Patients should be between 25 and 75 years old and with at least three-month history of chronic...

  • Therapeutic Angiogenesis. Vartanian, Shant M.; Sarkar, Rajabrata // Vascular & Endovascular Surgery;Jun/Jul2007, Vol. 41 Issue 3, p173 

    Myocarclial ischemia and peripheral vascular disease persist as significant clinical problems despite improved medical, surgical, and endovascular therapies. Advances in our understanding of the biological mechanisms that govern capillary neovascularization and collateral artery growth have...

  • Strategies to Improve Early Reperfusion in ST-Elevation Myocardial Infarction. Faxon, David P.; Jacobs, Alice K. // Reviews in Cardiovascular Medicine;Summer2007, Vol. 8 Issue 3, p127 

    The article focuses on the strategies to improve early reperfusion in ST-elevation myocardial infarction. It is known that rapid and complete reperfusion in ST-elevation myocardial infarction reduces infarct size and improves long-term morbidity and mortality rates. Randomized clinical trials...

  • Vascular viewpoint. Tran, Huyen // Vascular Medicine;2004, Vol. 9 Issue 1, p90 

    Question: Is a history of pre-existing atherothrombotic disease associated with an increased risk of subsequent ischemic events, and is it associated with a reduction in efficacy of clopidogrel? Population: Patients with recent ischemic stroke (IS), myocardial infarction (MI), or established...

  • Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. Toole, James F.; Malinow, M. René; Chambless, Lloyd E.; Spence, J. David; Pettigrew, L. Creed; Howard, Virginia J.; Sides, Elizabeth G.; Wang, Chin-Hua; Stampfer, Meir // JAMA: Journal of the American Medical Association;2/4/2004, Vol. 291 Issue 5, p565 

    Context: In observational studies, elevated plasma total homocysteine levels have been positively associated with ischemic stroke risk. However the utility of homocysteine-lowering therapy to reduce that risk has not been confirmed by randomized trials. Objective: To determine whether high doses...

  • No connection between the level of exposition to statins in the population and the incidence/ mortality of acute myocardial infarction: An ecological study based on Sweden's municipalities. Nilsson, Staffan; M�lstad, Sigvard; Karlberg, Catarina; Karlsson, Jan-Erik; Persson, Lars-G�ran // Journal of Negative Results in Biomedicine;2011, Vol. 10 Issue 1, p6 

    Background: Randomised controlled trials have shown an excellent preventive effect of statins on ischemic heart disease. Our objective was to investigate if a relation can be detected between acute myocardial infarction- (AMI) mortality or incidence and statin utilisation, for men and women in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics